Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.55 |
| ▸ | DRD3 | P35462 | 2/20 | 0.55 |
| ▸ | DPP4 | P27487 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | HTR2B | P41595 | 2/20 | 0.45 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | FUCA1 | P04066 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1895015 | 0.85 | DRD2 (0.56) | DRD2DRD3DPP4SIGMAR1HTR2A | |
| SCHEMBL1896006 | 0.85 | LMNA (0.44) | DRD2DRD3DPP4SIGMAR1HTR2A | |
| SCHEMBL1891551 | 0.85 | DPP4 (0.49) | DRD2DRD3DPP4SIGMAR1HTR2A | |
| SCHEMBL8497892 | 0.84 | DRD2 (0.50) | DRD2DRD3DPP4SIGMAR1HTR2A | |
| SCHEMBL8500244 | 0.84 | DRD2 (0.50) | DRD2DRD3DPP4SIGMAR1HTR2A | |
| SCHEMBL8489329 | 0.84 | DRD2 (0.50) | DRD2DRD3DPP4SIGMAR1HTR2A | |
| SCHEMBL1895022 | 0.84 | DRD2 (0.55) | DRD2DRD3DPP4SIGMAR1S1PR1 | |
| SCHEMBL1895668 | 0.82 | DRD2 (0.58) | DRD2DRD3SIGMAR1HTR2AHTR2C | |
| SCHEMBL3075236 | 0.81 | DPP4 (0.47) | DRD2DRD3DPP4SIGMAR1HTR2A | |
| SCHEMBL3075231 | 0.81 | DPP4 (0.47) | DRD2DRD3DPP4SIGMAR1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096520-B2 | Tricyclic ideno-pyrrole derivatives as serotonin receptor modulators | ABT HOLDING COMPANY (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140206739-A1 | TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | ABT HOLDING COMPANY (US) | 2014-07-24 | — | — | US | disclosed |
| US-8716324-B2 | Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators | ATHERSYS, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20120252859-A1 | Tricyclic Indeno-Pyrrole Derivatives as Serotonin Receptor Modulators | ATHERSYS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-8232311-B2 | Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators | ATHERSYS, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110172283-A1 | Tricyclic Indeno-Pyrrole Derivatives as Serotonin Receptor Modulators | BENNANI YOUSSEF L | 2011-07-14 | — | — | US | disclosed |
| US-7935830-B2 | Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators | ATHERSYS, INC. (US) | 2011-05-03 | — | — | US | disclosed |
| US-20090239925-A1 | TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | ATHERSYS, INC. | 2009-09-24 | — | — | US | disclosed |
| EP-1841738-A2 | TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | Athersys, Inc. (US) | 2007-10-10 | — | — | EP | disclosed |
| WO-2007081299-A2 | TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | ATHERSYS, INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| US-20060025601-A1 | Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators | ATHERSYS, INC. | 2006-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252859-A1 | Tricyclic Indeno-Pyrrole Derivatives as Serotonin Receptor Modulators | HTR5A, HTR3E, HTR1E | DRD2 71/4885DRD3 146/4885DPP4 843/4885 |
| US-20110172283-A1 | Tricyclic Indeno-Pyrrole Derivatives as Serotonin Receptor Modulators | HTR5A, HTR3E, HTR1E | DRD2 71/4885DRD3 146/4885DPP4 843/4885 |
| US-20060025601-A1 | Tricyclic indeno-pyrrole derivatives as serotonin receptor modulators | HTR5A, HTR3E, HTR1E | DRD2 71/4885DRD3 146/4885DPP4 843/4885 |
| US-20090239925-A1 | TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | HTR5A, HTR3E, HTR1E | DRD2 71/4885DRD3 146/4885DPP4 843/4885 |
| US-20140206739-A1 | TRICYCLIC INDENO-PYRROLE DERIVATIVES AS SEROTONIN RECEPTOR MODULATORS | HTR5A, HTR3E, HTR1E | DRD2 71/4885DRD3 146/4885DPP4 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.